Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Leases (2019 - 2025)

Cytokinetics (CYTK) has disclosed Current Leases for 7 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases changed N/A to $19.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.1 million, a N/A change, with the full-year FY2025 number at $19.1 million, changed N/A from a year prior.
  • Current Leases was $19.1 million for Q4 2025 at Cytokinetics, down from $20.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $20.6 million in Q3 2025 to a low of $3.7 million in Q1 2021.
  • A 5-year average of $15.9 million and a median of $16.1 million in 2022 define the central range for Current Leases.
  • Biggest YoY gain for Current Leases was 433.68% in 2021; the steepest drop was 26.44% in 2021.
  • Cytokinetics' Current Leases stood at $14.9 million in 2021, then decreased by 13.68% to $12.8 million in 2022, then soared by 39.46% to $17.9 million in 2023, then grew by 5.39% to $18.9 million in 2024, then increased by 1.35% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Current Leases are $19.1 million (Q4 2025), $20.6 million (Q3 2025), and $19.6 million (Q2 2025).